Catégorie : Cannabis et Réduction des Risques

Association between medical cannabis laws and opioid overdose mortality has reversed over time, Chelsea L. Shover et al., 2019

Association between medical cannabis laws and opioid overdose mortality has reversed over time Chelsea L. Shover, Corey S. Davis, Sanford C. Gordon, and Keith Humphreys PNAS, mai 2019 www.pnas.org/cgi/doi/10.1073/pnas.1903434116   Abstract Medical cannabis has been touted as a solution to the US opioid overdose crisis since Bachhuber et al. [M. A. Bachhuber, B. Saloner, C. O. Cunningham, C. L. Barry, JAMA Intern. Med. 174, 1668–1673] found that from 1999 to 2010 states with medical cannabis laws experienced slower increases in opioid analgesic overdose mortality. That research received substantial attention in the scientific literature and popular press and served as a talking point for the cannabis industry [...]

Lire la suite

Medical Cannabis No Solution to the Opioid Crisis, Batya Swift Yasgur, 2019

Medical Cannabis No Solution to the Opioid Crisis Batya Swift Yasgur, MA, LSW Medscape Medical News, June 11, 2019 https://www.medscape.com/viewarticle/914256?nlid=130206_2052&src=WNL_mdplsnews_190614_mscpedit_psyc&uac=292598PZ&spon=12&impID=1994987&faf=1   Contrary to previous research and popular assumptions, legalization of, and broader access to, medical cannabis has not reduced opioid overdose death rates. A study at Stanford University in California showed no protective effect of medical cannabis. In fact, states that legalized medical cannabis actually experienced a 22.7% increase in opioid overdose deaths. "There has been an idea touted by people and the cannabis industry and everyone invested in finding solutions to the opioid crisis that passing cannabis laws is one way to do that," lead author [...]

Lire la suite

Study will test pot’s effects on infants’ brain development, Brian Donohue, UW Medicine School of Medecine, 2019

May 10, 2019 Study will test pot’s effects on infants’ brain development Researchers seek to isolate cannabis from concurrent use of alcohol, tobacco, and illicit drugs. Media Contact: Brian Donohue - 206.543.7856, bdonohue@uw.edu Kleinhans Lab MRI scans of infants’ brains are part of the evaluation to discern effects of prenatal marijuana exposure. UW Medicine researchers are recruiting pregnant women to study whether prenatal marijuana use – in the absence of alcohol, tobacco, and any illicit drug consumption – affects their infants’ brain development, cognitive and motor development, medical health, and social behavior. The “Moms + Marijuana” study is co-led by Drs. Natalia Kleinhans and Stephen Dager, radiologists at [...]

Lire la suite

Association Between Marijuana Use and Adverse Obstetrical and Neonatal Outcomes, C.R. Warshak, J. Regan et al., 2015

Association Between Marijuana Use and Adverse Obstetrical and Neonatal Outcomes CR Warshak; J Regan; B Moore; K Magner; S Kritzer; J Van Hook Journal of Perinatology, 2015, 35, 12, 991-995. PMID : 26401751 DOI : 10.1038/jp.2015.120 Abstract and Introduction Abstract Objective: To evaluate associations between marijuana exposure and adverse outcomes excluding women with polysubstance abuse and stratifying for concurrent maternal tobacco use. Study Design: We performed a retrospective cohort study evaluating various obstetrical and neonatal outcomes including: preterm delivery, pre-eclampsia, gestational diabetes, cesarean delivery, fetal growth restriction, a composite which included stillbirth or neonatal intensive care unit admission, and perinatal mortality. We stratified study groups [...]

Lire la suite

Marijuana and fertility, Sara Ilnitsky & Stan Van Uum, 2019

Marijuana and fertility Sara Ilnitsky MD, Stan Van Uum MD Canadian Medical Association Journal, 2019 June 10, 191, 23, E638. doi : 10.1503/cmaj.181577 CMAJ Podcasts: author interview at https://soundcloud.com/cmajpodcasts/181577-five   1 Tetrahydrocannabinol acts on the endocannabinoid system, which is ubiquitous in reproductive tissues Tetrahydrocannabinol, the active ingredient in marijuana, is a lipophilic compound with a prolonged half-life of 20–36 hours.1 Tetrahydrocannabinol activates the cannabinoid receptors, which are part of the endogenous endocannabinoid system. This system is found in the hypothalamus, pituitary and internal reproductive organs in both sexes.2,3 2 Marijuana use can decrease sperm count Smoking marijuana more than once weekly in the preceding 3 months (n = 130/1215) [...]

Lire la suite

Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder : A Double-Blind Randomized Placebo-Controlled Trial, Yasmin L. Hurd, Sharron Spriggs, et al., 2019

Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder : A Double-Blind Randomized Placebo-Controlled Trial Yasmin L. Hurd, Ph.D., Sharron Spriggs, M.A., Julia Alishayev, R.P.A., Gary Winkel, Ph.D., Kristina Gurgov, R.P.A., Chris Kudrich, D.H.Sc., Anna M. Oprescu, M.P.H., Edwin Salsitz, M.D. AJP in Advance, 2019, 1-12. doi: 10.1176/appi.ajp.2019.18101191   Objective : Despite the staggering consequences of the opioid epidemic, limited nonopioid medication options have been developed to treat this medical and public health crisis. This study investigated the potential of cannabidiol (CBD), a nonintoxicating phytocannabinoid, to reduce cue-induced craving and anxiety, two critical features of addiction that often [...]

Lire la suite

Has the Legalisation of Medical and Recreational Cannabis Use in the USA Affected the Prevalence of Cannabis Use and Cannabis Use Disorders ?Janni Leung et al., 2018

Has the Legalisation of Medical and Recreational Cannabis Use in the USA Affected the Prevalence of Cannabis Use and Cannabis Use Disorders ? Janni Leung, Chui Ying Vivian Chiu, Daniel Stjepanović & Wayne Hall Current Addiction Reports, 2018, 5, 403–417 https://doi.org/10.1007/s40429-018-0224-9 Published online: 21 September 2018 # Springer Nature Switzerland AG 2018 Abstract Purpose of Review Since California legalised medical use of cannabis in 1996, 29 other US states have done so. Eight US states have legalised the retail sale of cannabis to adults over the age of 21 years since 2012. Critics of these policy changes have suggested that they will increase the prevalence of cannabis [...]

Lire la suite

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition, T.R. Arkell et al., 2019

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Arkell T.R., Lintzeris N., Kevin R.C., Ramaekers J.G., Vandrey R., Irwin C., Haber P.S., McGregor I.S. Psychopharmacology (Berlin), 2019 DOI : 10.1007/s00213-019-05246-8 PMID : 31044290 Abstract BACKGROUND : The main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), can impair driving performance. Cannabidiol (CBD), a non-intoxicating cannabis component, is thought to mitigate certain adverse effects of THC. It is possible then that cannabis containing equivalent CBD and THC will differentially affect driving and cognition relative to THC-dominant cannabis. AIMS : The present study investigated and compared the effects of THC-dominant and [...]

Lire la suite

CANNABIS EN TÊTE, “Dopamine”, Mai 2019

CANNABIS EN TÊTE A propos du Dossier Central publié dans le N°237 de la Revue SANTÉ MENTALE "SCHIZOPHRÉNIE ET CANNABIS" - - - - - - - - - - DOPAMINE #05 (MAI 2019)   Sans créer de lien de causalité à la vas-vite, difficile de ne pas associer schizophrénie et usage de cannabis puisqu'un quart des patients souffrants de cette pathologie consomment régulièrement un produit qui n'est peut-être pas entré dans leur vie par hasard ou du moins qu'ils ont adopté pour soulager certains symptômes tout en en aggravant d'autres... Quant à la part de responsabilité du cannabis dans l'apparition d'une schizophrénie, un certain nombre [...]

Lire la suite

Potency Analysis of Medical Marijuana Products from New York State, Lingyun Li et al., 2019

Potency Analysis of Medical Marijuana Products from New York State Lingyun Li, Bryan C. Duffy, Lorie A. Durocher, Mark A. Dittmar, Robert A. Acosta, Emily R. Delaney, Lei Li, Kenneth M. Aldous and David C. Spink Cannabis and Cannabinoid Research,  Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0037 Abstract Introduction : In the United States, medicalmarijuana programs have been established in 29 states and the District of Columbia. In 2014, New York State (NYS) approved medical marijuana legislation, and its program became fully operational in January of 2016. Products manufactured under the auspices of the program may be used by certified patients in [...]

Lire la suite